Literature DB >> 20425374

Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.

Constantine S Tam1, Issa Khouri.   

Abstract

Myeloablative allogeneic stem cell transplantation carries the promise of long-term disease control by graft-versus-lymphoma (GVL) immunity but is associated with a 30% to 40% risk of transplant-related mortality. Nonmyeloablative stem cell transplantation (NST) aims to exploit the GVL effect without the attendant toxicity of myeloablative conditioning. At the M.D. Anderson Cancer Center, the standard NST conditioning regimen for patients with follicular lymphoma is fludarabine, cyclophosphamide, and rituximab (FCR). Using this regimen, transplant-related mortality is currently 10%, and 85% of patients remain alive without disease at 3 to 4 years. This review discusses the current issues in NST for follicular lymphomas, including the optimization of conditioning intensity, the use of rituximab in immunomodulation, and the role of donor lymphocyte infusion.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 20425374     DOI： 10.1007/s11899-007-0031-1

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  32 in total

1.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

Authors:  N Di Gaetano; Y Xiao; E Erba; R Bassan; A Rambaldi; J Golay; M Introna
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

2.  CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.

Authors:  Frank J Hsu; Marina Komarovskaya
Journal:  J Immunother       Date:  2002 Nov-Dec       Impact factor: 4.456

3.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

5.  Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan.

Authors:  E Kusumi; M Kami; Y Kanda; N Murashige; Y Kishi; R Suzuki; K Takeuchi; T E Tanimoto; T Mori; K Muta; T Tamaki; Y Tanaka; H Ogawa; T Yamane; S Taniguchi; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2005-08       Impact factor: 5.483

6.  Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

Authors:  Roberto Rodriguez; Auayporn Nademanee; Nora Ruel; Eileen Smith; Amrita Krishnan; Leslie Popplewell; Jasmine Zain; Kathy Patane; Neil Kogut; Ryotaro Nakamura; Clarence Sarkodee-Adoo; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2006-12       Impact factor: 5.742

7.  Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Authors:  Stéphane Vigouroux; Mauricette Michallet; Raphaël Porcher; Michel Attal; Lionel Ades; Marc Bernard; Didier Blaise; Reza Tabrizi; Frédéric Garban; Jill-Patrice Cassuto; Patrice Chevalier; Thierry Facon; Norbert Ifrah; Marc Renaud; Hervé Tilly; Jean-Paul Vernant; Mathieu Kuentz; Jean-Henri Bourhis; Pierre Bordigoni; Eric Deconinck; Bruno Lioure; Gérard Socié; Noël Milpied
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

8.  Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.

Authors:  Philip J Bierman; John W Sweetenham; Fausto R Loberiza; Goli Taghipour; Hillard M Lazarus; J Douglas Rizzo; Norbert Schmitz; Koen van Besien; Julie M Vose; Mary Horowitz; Anthony Goldstone
Journal:  J Clin Oncol       Date:  2003-09-08       Impact factor: 44.544

9.  Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.

Authors:  Katharine Branson; Rajesh Chopra; Panagiotis D Kottaridis; Grant McQuaker; Anne Parker; Stephen Schey; Ronjon K Chakraverty; Charles Craddock; Donald W Milligan; Ruth Pettengell; Judith C W Marsh; David C Linch; Anthony H Goldstone; Catherine D Williams; Stephen Mackinnon
Journal:  J Clin Oncol       Date:  2002-10-01       Impact factor: 44.544

10.  Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.

Authors:  K R Schultz; J Paquet; S Bader; K T HayGlass
Journal:  Bone Marrow Transplant       Date:  1995-08       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.